David Carpenter, Chairman of the Berkshire Research Ethics Committee, which approved the Oxford coronavirus vaccine trial said the vaccine could be available as early as September.
“Nobody can put ﬁnal dates… things might go wrong but the reality is that by working with a big pharma company, that vaccine could be fairly widely available around September and that is the sort of target they are working on,” David Carpenter said. he vaccine development, by the university’s Jenner Institute, is being supported by the UK government and AstraZeneca, which will support the production phase. Blood samples taken from a group of UK volunteers given a dose of the vaccine showed that it stimulated the body to produce both antibodies and “killer T-cells.” The source cautioned that the results, while “extremely promising”, did not yet prove that the Oxford vaccine provides long-lasting immunity against the deadly virus.
The vaccine, named ChAdOx1 nCoV-19, is based on a weakened version of the common cold that causes infections in chimpanzees. It also contains the genetic material of the spike protein of SARS-CoV-2 – the strain of coronavirus that causes the COVID-19 illness. On the other part, Britain also has secured access to 90 million doses of two possible Covid-19 vaccines from an alliance of Pﬁzer and BioNTech, and French group Valneva, the business ministry said on Monday, July 20.